Skip to main content

Table 1 Demographic data of trial subjects.

From: A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

  

20-40 Y

41-64 Y

Total

  

N = 50

N = 50

N = 100

Characteristics

Parameters or

Categories

Value

or n

%

Value

or n

%

Value

or n

%

Age (years)

Mean

31.1

-

49.6

-

40.3

-

 

SD

5.69

-

6.04

-

10.89

-

 

Median

31

-

49

-

40.5

-

 

Minimum

20

-

41

-

20

-

 

Maximum

40

-

63

-

63

-

Gender

Female

25

50

32

64

57

57

 

Male

25

50

18

36

43

43

Race

Asian-Japanese heritage

50

100

50

100

100

100

Height (cm)

Mean

165.9

-

162.5

-

164.2

-

 

SD

8.41

-

7.46

-

8.1

-

 

Median

164

-

161.5

-

163

-

Weight (kg)

Mean

60.7

-

60.6

-

60.6

-

 

SD

12.13

-

11.28

-

11.65

-

 

Median

61

-

57.6

-

59

-

  1. 20-40 Y = subjects aged 20-40 years; 41-64 Y = subjects aged 41-64 years; N = total number of subjects;
  2. n/% = number/percentage of subjects in a given category; value = value of the considered parameter;
  3. SD = standard deviation
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us